Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP2) and Direct Impairment of its Canonical Function: Implications for the Therapeutic Potential of Lacosamide

Molecular Neurobiology

Volumn 51, Issue 2, 2015, Pages 599-609

  Wilson, Sarah M ^a   Khanna, Rajesh ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

CRMP2; Epileptogenesis; Lacosamide; Slow inactivation; Sodium channels

Indexed keywords

ACETAMIDE DERIVATIVE; COLLAPSIN RESPONSE MEDIATOR PROTEIN-2; LACOSAMIDE; NERVE PROTEIN; PROTEIN BINDING; SIGNAL PEPTIDE;

ANIMAL; CHEMISTRY; EPILEPSY; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ACETAMIDES; ANIMALS; EPILEPSY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84939894431     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8775-9     Document Type: Review

References (83)

1. Biton V (2012) Lacosamide for the treatment of partial-onset seizures. Expert Rev Neurother 12(6):645–655. doi:10.1586/ern.12.50
2. Cortes S, Liao ZK, Watson D, Kohn H (1985) Effect of structural modification of the hydantoin ring on anticonvulsant activity. J Med Chem 28(5):601–606
3. Choi D, Stables JP, Kohn H (1996) The anticonvulsant activities of functionalized N-benzyl 2-acetamidoacetamides. The importance of the 2-acetamido substituent. Bioorg Med Chem 4(12):2105–2114
4. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E (2001) Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 43(1):11–58
5. Duncan GE, Kohn H (2005) The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 67(1–2):81–87. doi:10.1016/j.eplepsyres.2005.08.009
6. Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White HS (2007) Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 74(2–3):147–154. doi:10.1016/j.eplepsyres.2007.03.004
7. Perucca E, Yasothan U, Clincke G, Kirkpatrick P (2008) Lacosamide. Nat Rev Drug Discov 7(12):973–974
8. EMA EMA (2012) Vimpat. EPAR summary for the public. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000863/human_med_001139.jsp&mid=WC0b01ac058001d124
9. Markoula S, Teotonio R, Ratnaraj N, Duncan JS, Sander JW, Patsalos PN (2014) Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit. doi:10.1097/FTD.0000000000000051
10. Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojarvi J, Doty P (2010) Examining the clinical utility of lacosamide: Pooled analyses of three phase II/III clinical trials. CNS Drugs 24(12):1041–1054. doi:10.2165/11586830-000000000-00000
11. Beydoun A, D’Souza J, Hebert D, Doty P (2009) Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 9(1):33–42. doi:10.1586/14737175.9.1.33
12. Errington AC, Coyne L, Stohr T, Selve N, Lees G (2006) Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50(8):1016–1029. doi:10.1016/j.neuropharm.2006.02.002
13. Errington AC, Stohr T, Heers C, Lees G (2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73(1):157–169
14. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T (2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13(1):21–42
15. Park KD, Morieux P, Salome C, Cotten SW, Reamtong O, Eyers C, Gaskell SJ, Stables JP, Liu R, Kohn H (2009) Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J Med Chem 52(21):6897–6911
16. Park KD, Stables JP, Liu R, Kohn H (2010) Proteomic searches comparing two (R)-lacosamide affinity baits: an electrophilic arylisothiocyanate and a photoactivated arylazide group. Org Biomol Chem 8(12):2803–2813. doi:10.1039/c000987c
17. Wang LH, Strittmatter SM (1996) A family of rat CRMP genes is differentially expressed in the nervous system. J Neurosci 16(19):6197–6207
18. Schmidt EF, Strittmatter SM (2007) The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 600:1–11
19. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J (2003) Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 28(1):51–64
20. Hensley K, Venkova K, Christov A, Gunning W, Park J (2011) Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Molecular Neurobiology 43(3):180–91
21. Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shiromizu T, Watanabe H, Inagaki N, Iwamatsu A, Hotani H, Kaibuchi K (2002) CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol 4(8):583–591
22. Chae YC, Lee S, Heo K, Ha SH, Jung Y, Kim JH, Ihara Y, Suh PG, Ryu SH (2009) Collapsin response mediator protein-2 regulates neurite formation by modulating tubulin GTPase activity. Cell Signal 21(12):1818–1826. doi:10.1016/j.cellsig.2009.07.017
23. Arimura N, Inagaki N, Chihara K, Menager C, Nakamura N, Amano M, Iwamatsu A, Goshima Y, Kaibuchi K (2000) Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 275(31):23973–23980
24. Brown M, Jacobs T, Eickholt B, Ferrari G, Teo M, Monfries C, Qi RZ, Leung T, Lim L, Hall C (2004) Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J Neurosci: Off J Soc Neurosci 24(41):8994–9004. doi:10.1523/jneurosci.3184-04.2004
25. Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN, Sutherland C (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279(48):50176–50180. doi:10.1074/jbc.C400412200
26. Arimura N, Menager C, Kawano Y, Yoshimura T, Kawabata S, Hattori A, Fukata Y, Amano M, Goshima Y, Inagaki M, Morone N, Usukura J, Kaibuchi K (2005) Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol Cell Biol 25(22):9973–9984
27. Uchida Y, Ohshima T, Yamashita N, Ogawara M, Sasaki Y, Nakamura F, Goshima Y (2009) Semaphorin3A signaling mediated by Fyn-dependent tyrosine phosphorylation of collapsin response mediator protein 2 at tyrosine 32. J Biol Chem 284(40):27393–27401. doi:10.1074/jbc.M109.000240
28. Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N, Nakamura F, Takei K, Ihara Y, Mikoshiba K, Kolattukudy P, Honnorat J, Goshima Y (2005) Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: Implication of common phosphorylating mechanism underlying axon guidance and Alzheimer’s disease. Genes Cells 10(2):165–179
29. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3[beta] regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120(1):137–149. doi:10.1016/j.cell.2004.11.012
30. Cole AR, Causeret F, Yadirgi G, Hastie CJ, McLauchlan H, McManus EJ, Hernandez F, Eickholt BJ, Nikolic M, Sutherland C (2006) Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem 281(24):16591–16598. doi:10.1074/jbc.M513344200
31. Hou ST, Jiang SX, Aylsworth A, Ferguson G, Slinn J, Hu H, Leung T, Kappler J, Kaibuchi K (2009) CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J Neurochem 111(3):870–881
32. Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM, Molosh AI, You H, Hudmon A, Shekhar A, White FA, Zamponi GW, Brustovetsky N, Chen J, Khanna R (2011) Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem 286(43):37778–37792. doi:10.1074/jbc.M111.255455
33. Brittain JM, Pan R, You H, Brustovetsky T, Brustovetsky N, Zamponi GW, Lee WH, Khanna R (2012) Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels (Austin) 6(1):52–9
34. Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H, Kaibuchi K (2003) CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat Cell Biol 5(9):819–826
35. Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H, Takenawa T, Kaibuchi K (2005) CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol Cell Biol 25(22):9920–9935. doi:10.1128/MCB.25.22.9920-9935.2005
36. Kimura T, Watanabe H, Iwamatsu A, Kaibuchi K (2005) Tubulin and CRMP-2 complex is transported via Kinesin-1. J Neurochem 93(6):1371–1382
37. Lykissas MG, Batistatou AK, Charalabopoulos KA, Beris AE (2007) The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res 4(2):143–151
38. Arimura N, Kimura T, Nakamuta S, Taya S, Funahashi Y, Hattori A, Shimada A, Ménager C, Kawabata S, Fujii K, Iwamatsu A, Segal RA, Fukuda M, Kaibuchi K (2009) Anterograde transport of TrkB in axons is mediated by direct interaction with Slp1 and Rab27. Dev Cell 16(5):675–686. doi:10.1016/j.devcel.2009.03.005
39. Rahajeng J, Giridharan SS, Naslavsky N, Caplan S (2010) Collapsin response mediator protein-2 (Crmp2) regulates trafficking by linking endocytic regulatory proteins to dynein motors. J Biol Chem 85(42):31918–22
40. Khanna R, Wilson SM, Brittain JM, Weimer J, Sultana R, Butterfield A, Hensley K (2012) Opening Pandora’s jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol 7(6):749–771. doi:10.2217/fnl.12.68
41. Beyreuther B, Stohr T, Freitag J (2009) Method for identifying crmp modulators. Google Patents
42. Park KD, Kim D, Reamtong O, Eyers C, Gaskell SJ, Liu R, Kohn H (2011) Identification of a lacosamide binding protein using an affinity bait and chemical reporter strategy: 14-3-3 zeta. J Am Chem Soc 133(29):11320–11330. doi:10.1021/ja2034156
43. Wang Y, Brittain JM, Jarecki BW, Park KD, Wilson SM, Wang B, Hale R, Meroueh SO, Cummins TR, Khanna R (2010) In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein 2 (CRMP-2) identifies a pocket important in modulating sodium channel slow inactivation. J Biol Chem 285(33):25296–307
44. Sousa SF, Fernandes PA, Ramos MJ (2006) Protein-ligand docking: Current status and future challenges. Proteins 65(1):15–26. doi:10.1002/prot.21082
45. Delorenzo RJ, Sun DA, Deshpande LS (2005) Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintenance of epilepsy. Pharmacol Ther 105(3):229–266. doi:10.1016/j.pharmthera.2004.10.004
46. Wang Y, Khanna R (2011) Calcium channels are not affected by the anti-epileptic drug lacosamide. Transl Neurosci 2(1):13–22
47. Zhang JF, Randall AD, Ellinor PT, Horne WA, Sather WA, Tanabe T, Schwarz TL, Tsien RW (1993) Distinctive pharmacology and kinetics of cloned neuronal Ca2+ channels and their possible counterparts in mammalian CNS neurons. Neuropharmacology 32(11):1075–1088
48. Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87(4):387–406
49. Wilson SM, Xiong W, Wang Y, Ping X, Head JD, Brittain JM, Gagare PD, Ramachandran PV, Jin X, Khanna R (2012) Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization. Neuroscience 210:451–466. doi:10.1016/j.neuroscience.2012.02.038
50. Wolff C, Carrington B, Varrin-Doyer M, Vandendriessche A, Van der Perren C, Famelart M, Gillard M, Foerch P, Rogemond V, Honnorat J, Lawson A, Miller K (2012) Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2). CNS Neurosci Ther 18(6):493–500. doi:10.1111/j.1755-5949.2012.00313.x
51. Johnsson B, Lofas S, Lindquist G (1991) Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 198(2):268–277
52. Phizicky EM, Fields S (1995) Protein-protein interactions: Methods for detection and analysis. Microbiol Rev 59(1):94–123
53. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S (2010) Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun 1:100. doi:10.1038/ncomms1093
54. Chang BS, Lowenstein DH (2003) Epilepsy. N Engl J Med 349(13):1257–1266. doi:10.1056/NEJMra022308
55. Salin P, Tseng GF, Hoffman S, Parada I, Prince DA (1995) Axonal sprouting in layer V pyramidal neurons of chronically injured cerebral cortex. J Neurosci: Off J Soc Neurosci 15(12):8234–8245
56. Golarai G, Greenwood AC, Feeney DM, Connor JA (2001) Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury. J Neurosci: Off J Soc Neurosci 21(21):8523–8537
57. Kharatishvili I, Nissinen JP, McIntosh TK, Pitkanen A (2006) A model of posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats. Neuroscience 140(2):685–697. doi:10.1016/j.neuroscience.2006.03.012
58. Jin X, Prince DA, Huguenard JR (2006) Enhanced excitatory synaptic connectivity in layer v pyramidal neurons of chronically injured epileptogenic neocortex in rats. J Neurosci 26(18):4891–4900
59. Graber KD, Prince DA (2004) A critical period for prevention of posttraumatic neocortical hyperexcitability in rats. Ann Neurol 55(6):860–870. doi:10.1002/ana.20124
60. Prince DA, Parada I, Scalise K, Graber K, Jin X, Shen F (2009) Epilepsy following cortical injury: Cellular and molecular mechanisms as targets for potential prophylaxis. Epilepsia 50:30–40. doi:10.1111/j.1528-1167.2008.02008.x
61. McKinney RA, Debanne D, Gahwiler BH, Thompson SM (1997) Lesion-induced axonal sprouting and hyperexcitability in the hippocampus in vitro: Implications for the genesis of posttraumatic epilepsy. Nat Med 3(9):990–996
62. Czech T, Yang JW, Csaszar E, Kappler J, Baumgartner C, Lubec G (2004) Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 29(12):2189–2196
63. Bretin S, Reibel S, Charrier E, Maus-Moatti M, Auvergnon N, Thevenoux A, Glowinski J, Rogemond V, Premont J, Honnorat J, Gauchy C (2005) Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol 486(1):1–17. doi:10.1002/cne.20465
64. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang T, Hayes RL, Wang KK (2007) Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma 24(3):460–472. doi:10.1089/neu.2006.0078
65. Brown M, Jacobs T, Eickholt B, Ferrari G, Teo M, Monfries C, Qi RZ, Leung T, Lim L, Hall C (2004) Alpha2-chimaerin, cyclin-dependent Kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J Neurosci 24(41):8994–9004
66. Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N, Nakamura F, Takei K, Ihara Y, Mikoshiba K, Kolattukudy P, Honnorat J, Goshima Y (2005) Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: Implication of common phosphorylating mechanism underlying axon guidance and Alzheimer’s disease. Genes Cells: Devoted Mol Cell Mech 10(2):165–179. doi:10.1111/j.1365-2443.2005.00827.x
67. Sato Y, Ishida-Nakajima W, Kawamura M, Miura S, Oguma R, Arai H, Takahashi T (2011) Hypoxia-ischemia induces hypo-phosphorylation of collapsin response mediator protein 2 in a neonatal rat model of periventricular leukomalacia. Brain Res 1386:165–174. doi:10.1016/j.brainres.2011.02.027
68. Wilson SM, Yeon SK, Yang XF, Park KD, Khanna R (2014) Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury. Front Cell Neurosci 8:14. doi:10.3389/fncel.2014.00135
69. Lee C-Y, Jaw T, Tseng H-C, Chen IC, Liou H-H (2012) Lovastatin modulates glycogen synthase kinase-3β pathway and inhibits mossy fiber sprouting after pilocarpine-induced status epilepticus. PLoS One 7(6):e38789. doi:10.1371/journal.pone.0038789
70. Brandt C, Heile A, Potschka H, Stoehr T, Löscher W (2006) Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47(11):1803–1809. doi:10.1111/j.1528-1167.2006.00818.x
71. Loscher W, Brandt C (2010) Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 62(4):668–700. doi:10.1124/pr.110.003046
72. Loscher W (2002) Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 50(1–2):105–123
73. Loscher W, Honack D, Rundfeldt C (1998) Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284(2):474–479
74. Wasterlain CG, Stohr T, Matagne A (2011) The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res 94(1–2):10–17. doi:10.1016/j.eplepsyres.2010.12.014
75. Wang B, Dawson H, Wang H, Kernagis D, Kolls BJ, Yao L, Laskowitz DT (2012) Lacosamide improves outcome in a murine model of traumatic brain injury. Neurocrit Care. doi:10.1007/s12028-012-9808-8
76. Pitkanen A, Immonen R, Ndode-Ekane X, Grohn O, Stohr T, Nissinen J (2014) Effect of lacosamide on structural damage and functional recovery after traumatic brain injury in rats. Epilepsy Res 108(4):653–665. doi:10.1016/j.eplepsyres.2014.02.001
77. Licko T, Seeger N, Zellinger C, Russmann V, Matagne A, Potschka H (2013) Lacosamide treatment following status epilepticus attenuates neuronal cell loss and alterations in hippocampal neurogenesis in a rat electrical status epilepticus model. Epilepsia. doi:10.1111/epi.12196
78. Santhakumar V, Aradi I, Soltesz I (2005) Role of mossy fiber sprouting and mossy cell loss in hyperexcitability: a network model of the dentate gyrus incorporating cell types and axonal topography. J Neurophysiol 93(1):437–453. doi:10.1152/jn.00777.2004
79. Heng K, Haney MM, Buckmaster PS (2013) High-dose rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy. Epilepsia 54(9):1535–1541. doi:10.1111/epi.12246
80. Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, Zamponi N, Cappanera S, Grosso S, Kluger G, Janello C, Franzoni E, Elia M, Spalice A, Coppola G, Striano P, Pavone P, Savasta S, Viri M, Romeo A, Aloisi P, Gobbi G, Ferretti A, Cusmai R, Curatolo P (2013) Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure: J Br Epilepsy Assoc 22(3):210–216. doi:10.1016/j.seizure.2012.12.009
81. Kim JS, Kim H, Lim BC, Chae JH, Choi J, Kim KJ, Hwang YS, Hwang H (2013) Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. Brain Dev. doi:10.1016/j.braindev.2013.07.003
82. Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P (2014) Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol: EJPN: Off J Eur Paediatr Neurol Soc 18(1):55–59. doi:10.1016/j.ejpn.2013.08.006
83. Tomson T, Landmark CJ, Battino D (2013) Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications. Epilepsia 54(3):405–414. doi:10.1111/epi.12109